Esophageal and Esophagogastric Junction Cancers, Version 1.2015

Jaffer A. Ajani(The University of Texas MD Anderson Cancer Center), Thomas A. D’Amico(Duke University), Khaldoun Almhanna(University of South Florida), David J. Bentrem(Northwestern University), Stephen Besh(University of Tennessee Health Science Center), Joseph Chao(City Of Hope National Medical Center), Prajnan Das(The University of Texas MD Anderson Cancer Center), Crystal S. Denlinger(Fox Chase Cancer Center), Paul T. Fanta(University of California San Diego), Charles S. Fuchs(Brigham and Women's Hospital), Hans Gerdes(Memorial Sloan Kettering Cancer Center), Robert E. Glasgow(University of Utah), James A. Hayman(University of Michigan), Steven N. Hochwald(Roswell Park Comprehensive Cancer Center), Wayne L. Hofstetter(The University of Texas MD Anderson Cancer Center), David H. Ilson(Memorial Sloan Kettering Cancer Center), Dawn E. Jaroszewski(Mayo Clinic), Kory Jasperson(University of Utah), Rajesh N. Keswani(Northwestern University), Lawrence Kleinberg(Johns Hopkins University), W. Michael Korn(University of California, San Francisco), Stephen Leong(University of Colorado Denver), A. Craig Lockhart(Washington University in St. Louis), Mary F. Mulcahy(Northwestern University), Mark B. Orringer(University of Michigan), James Posey(University of Alabama at Birmingham), George A. Poultsides(Stanford University), Aaron R. Sasson(University of Nebraska Medical Center), Walter J. Scott(Fox Chase Cancer Center), Vivian E. Strong(Memorial Sloan Kettering Cancer Center), Thomas K. Varghese(Seattle Cancer Care Alliance), M. Kay Washington(Vanderbilt University), Christopher G. Willett(Duke University), Cameron D. Wright(Harvard University Press), Debra Zelman(Dream Foundation), Nicole R. McMillian, Hema Sundar
Journal of the National Comprehensive Cancer Network
February 1, 2015
10.6004/jnccn.2015.0028
Cited by 653Open Access
Full Text

Abstract

Esophageal cancer is the sixth most common cause of cancer deaths worldwide. Adenocarcinoma is more common in North America and Western European countries, originating mostly in the lower third of the esophagus, which often involves the esophagogastric junction (EGJ). Recent randomized trials have shown that the addition of preoperative chemoradiation or perioperative chemotherapy to surgery significantly improves survival in patients with resectable cancer. Targeted therapies with trastuzumab and ramucirumab have produced encouraging results in the treatment of advanced or metastatic EGJ adenocarcinomas. Multidisciplinary team management is essential for patients with esophageal and EGJ cancers. This portion of the NCCN Guidelines for Esophageal and EGJ Cancers discusses management of locally advanced adenocarcinoma of the esophagus and EGJ.

Related Papers

No related papers found

Powered by citation graph analysis